Stock Analiz

Zhengye Biotechnology Holding Ltd ZYBT

Biotechnology: Pharmaceutical Preparations · IPO 2025 · data as of November 13, 2026

$1.50Market cap $71M
Open the interactive analysis →

Zhengye Biotechnology Holding Ltd (ZYBT) is a healthcare company listed in the US with a market value of about $71M. In fiscal year 2025 it had revenue of $17M and net income of -$10M, a net margin of -60.0%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).

Key numbers: a price to free cash flow of 40.2, a 5-year average ROIC of -8%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 93% below the current price.

About Zhengye Biotechnology Holding

Zhengye Biotechnology Holding is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2025. It was profitable in 1 of the last 2 years in our data. It spends 15% of revenue on research and development.

Score: 1.0 / 5

Value0/5
Future growth1/5
Track record0/5
Financial health4/5
Shareholder returns0/5

Checks passed

  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Positive free cash flow
  • Debt below 3 years of free cash flow
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF40.2
P/S4.1
P/B2.0
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield2.5%
Shareholder yield0.0%
Intrinsic value vs. price−93%

Growth and quality

Revenue growth (1 yr)-34.8%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-27.0%
ROIC (5-yr avg.)-8.1%
Profitable years (of last 10)1
Years paying a dividend1

Financials, last 2 years

Fiscal year20252024
Revenue$17M$26M
Net income-$10M$2M
Free cash flow$2M$4M
EPS (diluted)$-0.21$0.03
Net margin-60.0%6.1%
ROIC-21.4%5.2%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Zhengye Biotechnology Holding stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 93% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Zhengye Biotechnology Holding pay a dividend?

Not currently.

Is Zhengye Biotechnology Holding a good stock to buy?

We do not give buy or sell advice. Zhengye Biotechnology Holding scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.